Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Madison O'Brien

Physician Assistant Canton, GA Physician Assistant

NPI 1851973267 CMS profile 11254436

1495 Hickory Flat Hwy Ste 100, Canton, GA 30115

Open in the dashboard

General payments

$4,888

243 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madison O'Brien of Canton, GA is reported in the CMS Open Payments database as having received $4,888 across 243 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $700 34
2024 General $746 30
2023 General $1,642 88
2022 General $1,370 62
2021 General $430 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madison O'Brien
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Madison O'Brien were reported at $700. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Madison O'Brien Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $430 $132 $37–$438 $132
2022 $1,370 $155 $48–$522 $149
2023 $1,642 $167 $52–$557 $160
2024 $746 $178 $55–$600 $164
2025 $700 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $812 37 payments
  2. Janssen Biotech, Inc. $548 28 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $433 25 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $398 24 payments
  5. Celgene Corporation $293 19 payments
  6. Genzyme Corporation $204 8 payments
  7. Intercept Pharmaceuticals, Inc. $203 7 payments
  8. Regeneron Healthcare Solutions, Inc. $192 9 payments
  9. Medtronic, Inc. $188 2 payments
  10. Merck Sharp & Dohme Corporation $174 8 payments
  11. Other $1,444 76 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,747 241 payments
  2. Education $141 2 payments
Products named General payments · program years 2021–2025
  1. ENTYVIO $412 24 payments
  2. RINVOQ $382 15 payments
  3. STELARA $364 21 payments
  4. XIFAXAN $359 21 payments
  5. ZEPOSIA $277 18 payments
  6. CREON $244 11 payments
  7. DUPIXENT $224 9 payments
  8. OCALIVA $203 7 payments
  9. TREMFYA $184 7 payments
  10. DIFICID $174 8 payments
  11. Other $2,573 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

381

Median for Physician Assistant: 241

Drug cost

$19,869

Median for Physician Assistant: $4,110

Branded share of claims

8.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 17 $12,770
Dexlansoprazole Dr Dexlansoprazole Brand 14 $2,546
Pantoprazole Sodium Generic 169 $2,194
Famotidine Generic 89 $862
Omeprazole Generic 75 $853
Esomeprazole Magnesium Generic 17 $643

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $93
  • GENZYME CORPORATION $38
$131 — —
RINVOQ
  • AbbVie, Inc. $87
$87 — —
DIFICID
  • Merck Sharp & Dohme Corporation $48
$48 — —
OMVOH
  • Lilly USA, LLC $32
$32 — —
CREON
  • AbbVie, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

243 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record